1. Home
  2. URGN vs DCO Comparison

URGN vs DCO Comparison

Compare URGN & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$47.11

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Ducommun Incorporated

DCO

Ducommun Incorporated

HOLD

Current Price

$197.26

Market Cap

1.9B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
URGN
DCO
Founded
2004
1849
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2016
1995

Fundamental Metrics

Financial Performance
Metric
URGN
DCO
Price
$47.11
$197.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$29.29
$153.60
AVG Volume (30 Days)
795.1K
267.1K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.95
Revenue
$1,128,000.00
$824,730,000.00
Revenue This Year
$129.09
$7.40
Revenue Next Year
$70.96
$8.59
P/E Ratio
N/A
$100.56
Revenue Growth
N/A
4.85
52 Week Low
$15.86
$84.76
52 Week High
$48.19
$210.39

Technical Indicators

Market Signals
Indicator
URGN
DCO
Relative Strength Index (RSI) 67.57 63.99
Support Level $18.23 $165.13
Resistance Level N/A N/A
Average True Range (ATR) 2.39 8.58
MACD 0.35 1.68
Stochastic Oscillator 86.58 71.82

Price Performance

Historical Comparison
URGN
DCO

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

About DCO Ducommun Incorporated

Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.

Share on Social Networks: